PE20030898A1 - Preparacion liofilizada que comprende inmunocitoquinas - Google Patents
Preparacion liofilizada que comprende inmunocitoquinasInfo
- Publication number
- PE20030898A1 PE20030898A1 PE2003000131A PE2003000131A PE20030898A1 PE 20030898 A1 PE20030898 A1 PE 20030898A1 PE 2003000131 A PE2003000131 A PE 2003000131A PE 2003000131 A PE2003000131 A PE 2003000131A PE 20030898 A1 PE20030898 A1 PE 20030898A1
- Authority
- PE
- Peru
- Prior art keywords
- polyoxyethylensorbitan
- immunocytokines
- interquals
- glucosamine
- refers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
SE REFIERE A UNA PREPARACION FARMACEUTICA LIOFILIZADA QUE COMPRENDE i)INMUNOCITOQUINAS (EL CONJUGADO SE CARACTERIZA PORQUE LOS EXTREMOS CON TERMINACION CARBOXILO DE LAS DOS CADENAS PESADAS DE INMUNOGLOBULINA DE LOS ANTICUERPOS ESTAN UNIDOS CON LOS EXTREMOS DE TERMINACION N DE LA CITOQUINA QUE SE SELECCIONA DE INTERLEUQUINA (IL-2), INTERFERON, FACTOR DE CRECIMIENTO HEMATOPOYETICO); ii)AZUCAR (SACAROSA, LACTOSA, MALTOSA, TREHALOSA), O AMINOAZUCAR (GLUCOSAMINA, N-METIL-GLUCOSAMINA, GALACTOSAMINA, ACIDO NEURAMINICO), iii)AMINOACIDO (ARGININA, LISINA, ORNITINA), iv)AGENTE TENSIOACTIVO (NO IONICO, POLISORBATO, POLIMERO DE POLIOXIETILENO-POLIOXIPROPILENO, ESTER DE ACIDO GRASO POLIOXIETILENSORBITANO; MONOOLEATO DE POLIOXIETILENSORBITANO; MONOLAURATO DE POLIOXIETILENSORBITANO); iv)BUFFER; v)AGENTE ISOTONICO; TAMBIEN SE REFIERE A UNA PREPARACION FARMACEUTICA ACUOSA DE INMUNOCITOQUINAS QUE PUEDE OBTENERSE POR RECONSTITUCION DEL LIOFILIZADO QUE PRESENTA UN pH DE 5-8. LA PREPARACION ES ESTABLE, TIENE MAYOR TIEMPO DE VIDA INCLUSO A TEMPERATURAS ELEVADAS Y SE UTILIZA POR VIA PARENTERAL
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10204792A DE10204792A1 (de) | 2002-02-06 | 2002-02-06 | Lyophilisierte Zubereitung enthaltend Immuncytokine |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030898A1 true PE20030898A1 (es) | 2003-10-25 |
Family
ID=27588393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000131A PE20030898A1 (es) | 2002-02-06 | 2003-02-04 | Preparacion liofilizada que comprende inmunocitoquinas |
Country Status (17)
Country | Link |
---|---|
US (1) | US20050220758A1 (es) |
EP (1) | EP1471942A1 (es) |
JP (1) | JP4422485B2 (es) |
KR (1) | KR20040091015A (es) |
CN (1) | CN1627958A (es) |
AR (1) | AR038355A1 (es) |
AU (1) | AU2003244470B2 (es) |
BR (1) | BR0307448A (es) |
CA (1) | CA2475211A1 (es) |
DE (1) | DE10204792A1 (es) |
MX (1) | MXPA04007562A (es) |
PE (1) | PE20030898A1 (es) |
PL (1) | PL369754A1 (es) |
RU (1) | RU2316348C2 (es) |
TW (1) | TW200303756A (es) |
WO (1) | WO2003066102A1 (es) |
ZA (1) | ZA200407028B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
JP2006045162A (ja) * | 2004-08-06 | 2006-02-16 | Takeda Chem Ind Ltd | 注射用ペプチド含有組成物 |
JP4948410B2 (ja) * | 2004-08-17 | 2012-06-06 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il−1アンタゴニスト製剤 |
JPWO2007037330A1 (ja) * | 2005-09-28 | 2009-04-09 | 第一三共株式会社 | キノロン含有凍結乾燥製剤の製造方法 |
AR058567A1 (es) * | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Formulaciones de proteinas estables |
US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
DE102007050165B4 (de) * | 2007-10-19 | 2010-06-17 | Stiftung Tierärztliche Hochschule Hannover | Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung |
ES2525257T3 (es) * | 2009-02-25 | 2014-12-19 | Supratek Pharma, Inc. | Composiciones de ciclopolisacárido y de bendamustina |
TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Fgf-18之凍乾調配物 |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
CA2920192A1 (en) * | 2013-09-27 | 2015-04-02 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
CA2947396C (en) | 2014-04-28 | 2021-10-19 | Eisai R&D Management Co., Ltd. | Lyophilized formulation of hgf |
EP3431590B1 (en) | 2016-03-17 | 2021-07-28 | Eisai R&D Management Co., Ltd. | Method for producing activated hepatocyte growth factor (hgf) |
CN114224853B (zh) * | 2022-01-04 | 2022-09-23 | 山东新时代药业有限公司 | 聚乙二醇化重组人粒细胞刺激因子注射用冻干制剂 |
CN114515334B (zh) * | 2022-02-22 | 2024-02-20 | 史辛艺 | 一种脂肪间充质干细胞因子冻干粉及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0150067A3 (en) * | 1984-01-23 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
JPS61197527A (ja) * | 1985-02-25 | 1986-09-01 | Takeda Chem Ind Ltd | インタ−ロイキン−2組成物 |
EP0158487B1 (en) * | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
US5104651A (en) * | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
JP3822383B2 (ja) * | 1993-12-17 | 2006-09-20 | 持田製薬株式会社 | 可溶性トロンボモジュリン含有組成物 |
EP0689843B1 (en) * | 1993-12-17 | 2003-09-10 | Mochida Pharmaceutical Co., Ltd. | Composition containing soluble thrombomodulins |
US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
US5770700A (en) * | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
-
2002
- 2002-02-06 DE DE10204792A patent/DE10204792A1/de not_active Withdrawn
-
2003
- 2003-01-14 MX MXPA04007562A patent/MXPA04007562A/es not_active Application Discontinuation
- 2003-01-14 US US10/503,615 patent/US20050220758A1/en not_active Abandoned
- 2003-01-14 RU RU2004126942/15A patent/RU2316348C2/ru not_active IP Right Cessation
- 2003-01-14 BR BR0307448-0A patent/BR0307448A/pt not_active IP Right Cessation
- 2003-01-14 CA CA002475211A patent/CA2475211A1/en not_active Abandoned
- 2003-01-14 EP EP03737257A patent/EP1471942A1/de not_active Withdrawn
- 2003-01-14 PL PL03369754A patent/PL369754A1/xx not_active Application Discontinuation
- 2003-01-14 AU AU2003244470A patent/AU2003244470B2/en not_active Ceased
- 2003-01-14 CN CNA038033550A patent/CN1627958A/zh active Pending
- 2003-01-14 KR KR10-2004-7012214A patent/KR20040091015A/ko not_active Application Discontinuation
- 2003-01-14 WO PCT/EP2003/000259 patent/WO2003066102A1/de active Application Filing
- 2003-01-14 JP JP2003565525A patent/JP4422485B2/ja not_active Expired - Fee Related
- 2003-01-30 TW TW092102217A patent/TW200303756A/zh unknown
- 2003-02-04 PE PE2003000131A patent/PE20030898A1/es not_active Application Discontinuation
- 2003-02-05 AR ARP030100361A patent/AR038355A1/es unknown
-
2004
- 2004-09-02 ZA ZA200407028A patent/ZA200407028B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2475211A1 (en) | 2003-08-14 |
MXPA04007562A (es) | 2004-11-10 |
PL369754A1 (en) | 2005-05-02 |
AU2003244470B2 (en) | 2008-03-13 |
BR0307448A (pt) | 2004-12-28 |
WO2003066102A1 (de) | 2003-08-14 |
AU2003244470A1 (en) | 2003-09-02 |
JP4422485B2 (ja) | 2010-02-24 |
KR20040091015A (ko) | 2004-10-27 |
RU2004126942A (ru) | 2005-06-10 |
AR038355A1 (es) | 2005-01-12 |
DE10204792A1 (de) | 2003-08-14 |
RU2316348C2 (ru) | 2008-02-10 |
TW200303756A (en) | 2003-09-16 |
EP1471942A1 (de) | 2004-11-03 |
JP2005516998A (ja) | 2005-06-09 |
US20050220758A1 (en) | 2005-10-06 |
CN1627958A (zh) | 2005-06-15 |
ZA200407028B (en) | 2006-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030898A1 (es) | Preparacion liofilizada que comprende inmunocitoquinas | |
ATE454137T1 (de) | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab | |
Ellouz et al. | Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives | |
RU2011127913A (ru) | Составы, содержащие антитела | |
CA2272245A1 (en) | Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies | |
PE20030777A1 (es) | Preparacion liofilizada que contiene un anticuerpo contra el receptor egf | |
AR058567A1 (es) | Formulaciones de proteinas estables | |
ES2395035T3 (es) | Formulaciones de antagonistas de la IL-1 | |
EA200801756A1 (ru) | Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса | |
IS7671A (is) | Ónæmisvaka samsetningar | |
AR080427A1 (es) | Formulacion liquida para un conjugado de accion prolongada del g-csf | |
TR200101256T2 (tr) | DNA ile aşılamada geliştirmeler | |
DOP2001000224A (es) | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester. | |
DE3585696D1 (de) | Lyophilisierte hepatitis-b-vakzine. | |
PT1373108E (pt) | Processo e sistema para sincronizar cargas antes da injeccao num sistema de triagem do tipo com pratos basculantes | |
AR083338A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r) | |
PT1035133E (pt) | Proteinas de fusao compreendendo veiculos que podem induzir uma dupla resposta imune | |
US11707501B2 (en) | Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate | |
EA200400211A1 (ru) | Лиофилизованная композиция 2-метилтиенобензодиазепина | |
RU2009128327A (ru) | Лиофилизированная инъецируемая фармацевтическая композиция полусинтетических алкалоидов vinca и углевода, стабильная при комнатной температуре | |
ATE109158T1 (de) | Rubella-e1 und c peptide. | |
DE69219723D1 (de) | Montagerahmen für Einrichtungen zur berührungslosen Hochtemperaturkontrolle von Formkörpern, insbesondere aus Glas | |
BR9709993A (pt) | Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica | |
WO2001055181A3 (en) | Recombinant multivalent malarial vaccines against plasmodium vivax | |
CO4810235A1 (es) | Enterotoxina mutante efectiva como un coadyuvante no toxico para el vih |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |